

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2020/12/31	2019/12/31
Balance Sheet		
Current assets		
Cash and cash equivalents	291,141	193,671
Current financial assets at amortised cost	1,200	84,760
Current contract assets	101,779	22,667
Accounts receivable, net	66,947	93,111
Accounts receivable due from related parties, net	305	10,602
Other receivables	5,511	1,829
Current inventories	84,852	56,123
Prepayments	23,817	24,242
Other current assets	958	7,954
Total current assets	576,510	494,959
Non-current assets		
Non-current financial assets at fair value through other comprehensive income	191,810	149,305
Property, plant and equipment	690,078	545,077
Right-of-use assets	96,653	47,762
Intangible assets	60,641	74,850
Deferred tax assets	83,450	79,710
Other non-current assets	53,411	16,331
Total non-current assets	1,176,043	913,035
Total assets	1,752,553	1,407,994
Current liabilities		
Current borrowings	100,000	0
Current contract liabilities	125,904	91,686
Accounts payable	40,314	24,699
Other payables	132,279	87,979
Other payables to related parties	47	13,328
Current tax liabilities	645	0
Current lease liabilities	24,325	13,623
Other current liabilities	1,265	600
Total current liabilities	424,779	231,915
Non-current liabilities		
Deferred tax liabilities	6,681	3,806
Non-current lease liabilities	72,282	33,177
Other non-current liabilities	37,144	37,143
Total non-current liabilities	116,107	74,126
Total liabilities	540,886	306,041
Share capital		
Ordinary share	1,282,377	1,279,545
Advance receipts for share capital	499	0
Total Share Capital	1,282,876	1,279,545
Capital surplus		
Total capital surplus	53,113	260,908
Retained earnings		
Unappropriated retained earnings (accumulated deficit)	-207,233	-473,311
Total retained earnings	-207,233	-473,311
Other equity interest		
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	82,911	34,811
Total other equity interest	82,911	34,811
Total equity	1,211,667	1,101,953
Total liabilities and equity	1,752,553	1,407,994
Number of share capital awaiting retirement	0	0
Equivalent issue shares of advance receipts for ordinary share	159,000	0
Number of shares in entity held by entity and by its subsidiaries	0	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2020/4th	2019/4th
Income Statement		
Total operating revenue	665,341	390,844
Total operating costs	478,809	258,336
Gross profit (loss) from operations	186,532	132,508
Gross profit (loss) from operations	186,532	132,508
Operating expenses		
Selling expenses	45,015	35,802
Administrative expenses	48,750	41,341
Research and development expenses	46,502	284,567
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	10,867	1,052
Total operating expenses	151,134	362,762
Net operating income (loss)	35,398	-230,254
Non-operating income and expenses		
Total interest income	1,481	4,215
Total other income	4,177	8,053
Other gains and losses, net	-12,224	-10,067
Finance costs, net	865	1,921
Total non-operating income and expenses	-7,431	280
Profit (loss) from continuing operations before tax	27,967	-229,974
Total tax expense (income)	-2,981	-11,799
Profit (loss) from continuing operations	30,948	-218,175
Profit (loss)	30,948	-218,175
Other comprehensive income		
Gains (losses) on remeasurements of defined benefit plans	69	3,825
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	64,629	11,724
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	2,868	4,059
Components of other comprehensive income that will not be reclassified to profit or loss	61,830	11,490
Total other comprehensive income	61,830	11,490
Total comprehensive income	92,778	-206,685
Basic earnings per share		
Total basic earnings per share	0.24	-1.74
Diluted earnings per share		
Total diluted earnings per share	0.24	-1.74

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2020/4th	2019/4th
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	27,967	-229,974
Profit (loss) before tax	27,967	-229,974
Depreciation expense	120,944	109,013
Amortization expense	16,252	14,276
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	10,867	1,052
Interest expense	865	1,921
Interest income	-1,481	-4,215
Share-based payments	6,756	223
Loss (gain) on disposal of property, plan and equipment	2,735	1,225
Impairment loss on non-financial assets	-782	14,175
Other adjustments to reconcile profit (loss)	-1,404	-1,349
Total adjustments to reconcile profit (loss)	154,752	136,321
Decrease (increase) in contract assets	-79,112	-7,337
Decrease (increase) in accounts receivable	15,285	-40,025
Decrease (increase) in accounts receivable due from related parties	10,347	-10,359
Decrease (increase) in other receivable	-3,792	7,904
Decrease (increase) in inventories	-27,947	-9,881
Decrease (increase) in prepayments	425	-1,406
Adjustments for decrease (increase) in other current assets	6,597	-5,447
Decrease (increase) in other operating assets	-39	0
Total changes in operating assets	-78,236	-66,551
Increase (decrease) in contract liabilities	34,218	43,169
Increase (decrease) in accounts payable	15,615	-15,188
Increase (decrease) in other payable	20,661	-6,227
Increase (decrease) in other payable to related parties	-181	209
Adjustments for increase (decrease) in other current liabilities	665	264
Increase (decrease) in net defined benefit liability	0	-59
Total changes in operating liabilities	70,978	22,168
Total changes in operating assets and liabilities	-7,258	-44,383
Total adjustments	147,494	91,938
Cash inflow (outflow) generated from operations	175,461	-138,036
Interest paid	-1,582	-2,176
Income taxes refund (paid)	293	-531
Net cash flows from (used in) operating activities	174,172	-140,743
Cash flows from (used in) investing activities		
Proceeds from disposal of financial assets at fair value through other comprehensive income	22,124	0
Proceeds from disposal of financial assets at amortised cost	83,560	3,839
Acquisition of property, plant and equipment	-161,977	-140,599
Proceeds from disposal of property, plant and equipment	1,433	12,626
Increase in refundable deposits	-1,893	-203
Acquisition of intangible assets	-2,043	-897
Net cash inflows from business combination	-13,100	-117,900
Decrease in other financial assets	0	10,000
Increase in prepayments for business facilities	-98,240	-37,313
Interest received	1,553	4,252
Net cash flows from (used in) investing activities	-168,583	-266,195
Cash flows from (used in) financing activities		
Increase in short-term loans	100,000	0
Payments of lease liabilities	-18,299	-16,536
Proceeds from issuing shares	0	401,400
Exercise of employee share options	10,180	0
Net cash flows from (used in) financing activities	91,881	384,864
Net increase (decrease) in cash and cash equivalents	97,470	-22,074
Cash and cash equivalents at beginning of period	193,671	215,745
Cash and cash equivalents at end of period	291,141	193,671
Cash and cash equivalents reported in the statement of financial position	291,141	193,671

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

2020/12/31 Statement of Stockholders' Equity

Unit: NT\$ thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,279,545	0	1,279,545	260,908	-473,311	-473,311	34,811	34,811		1,101,953
Capital surplus used to offset accumulated deficits	0	0	0	-221,400	221,400	221,400	0	0		0
Profit (loss)	0	0	0	0	30,948	30,948	0	0		30,948
Other comprehensive income	0	0	0	0	55	55	61,775	61,775		61,830
Total comprehensive income	0	0	0	0	31,003	31,003	61,775	61,775		92,778
Share-based payments	0	0	0	6,756	0	0	0	0		6,756
Disposal of investments in equity instruments designated at fair value through other comprehensive income	0	0	0	0	13,675	13,675	-13,675	-13,675		0
Others	2,832	499	3,331	6,849	0	0	0	0		10,180
Total increase (decrease) in equity	2,832	499	3,331	-207,795	266,078	266,078	48,100	48,100		109,714
Equity at end of period	1,282,377	499	1,282,876	53,113	-207,233	-207,233	82,911	82,911		1,211,667

2019/12/31 Statement of Stockholders' Equity

Unit: NT\$ thousand

Accounting Title	Ordinary share	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,099,545	1,099,545	300,786	-519,697	-519,697	26,381	26,381		907,015
Capital surplus used to offset accumulated deficits	0	0	-261,501	261,501	261,501	0	0		0
Profit (loss)	0	0	0	-218,175	-218,175	0	0		-218,175
Other comprehensive income	0	0	0	3,060	3,060	8,430	8,430		11,490
Total comprehensive income	0	0	0	-215,115	-215,115	8,430	8,430		-206,685
Issue of shares	180,000	180,000	221,400	0	0	0	0		401,400
Share-based payments	0	0	223	0	0	0	0		223
Total increase (decrease) in equity	180,000	180,000	-39,878	46,386	46,386	8,430	8,430		194,938
Equity at end of period	1,279,545	1,279,545	260,908	-473,311	-473,311	34,811	34,811		1,101,953